Table 1 |
|||||
|
Prognostic factors associated with prostate cancer after different types of treatment and according to the level of extension. Patients with organ confined disease treated with radical prostatectomy (surgical or radiated), and patients with more extensive disease are presented separately. The database applied was PubMed, the presented papers were published during years 1989 – 2005. |
|||||
|
Organ confined disease, radical prostatectomy (surgical) |
|||||
|
|
|||||
|
Survival-associated prognosticators |
Progression-associated prognosticators |
||||
|
Prognosticator |
p value |
Reference |
Prognosticator |
p value |
Reference |
|
Tumour volume |
< 0.009 |
Salomon et al. |
Age |
< 0.01 |
Obek et al. |
|
Gleason score |
< 0.0002 |
Hoznek et al. |
Gleason score |
< 0.0001 |
Epstein et al. |
|
Surgical margin |
< 0.009 |
Hoznek et al. |
Capsular invasion |
< 0.001 |
Wheeler et al. |
|
Tranzitional zone |
< 0.04 |
Augustin et al. |
PSA* |
< 0.001 |
Salomon et al |
|
p53 |
< 0.011 |
Kuczyk et al. |
Surgical margin |
< 0.075 |
Bloom et al. |
|
Stage |
< 0.02 |
Kuczyk et al. |
E-cadherin |
< 0.005 |
Umbas et al. |
|
p27 |
< 0.01 |
Yang et al. |
IGF-1** |
< 0.05 |
Yu et al. |
|
Aneuploidy |
< 0.02 |
Zincke et al. |
Stage |
< 0.001 |
D'Amico et al. |
|
Ki-67 |
< 0.001 |
Bettencourt et al. |
MVD*** |
< 0.007 |
Halvorsin et al. |
|
cDNA microarray |
< 0.01 |
Susan et al. |
p27 |
< 0.008 |
Yang et al. |
|
Aneuploidy |
< 0.0001 |
Zincke et al. |
|||
|
Aneuploidy |
< 0.001 |
Ross et al. |
|||
|
Ki-67 |
< 0.02 |
Bubendorf et al. |
|||
|
MUC1 |
< 0.003 |
Lapointe et al. |
|||
|
Organ confined disease, radical prostatectomy (radiation) |
|||||
|
|
|||||
|
Survival-associated prognosticators |
Progression-associated prognosticators |
||||
|
Prognosticator |
p value |
Reference |
Prognosticator |
p value |
Reference |
|
Age |
< 0.02 |
Austin el al. |
|||
|
Age |
< 0.01 |
Neulander et al |
|||
|
Race |
< 0.02 |
Austin et al. |
|||
|
Gleason score |
< 0.001 |
Kupelian et al. |
|||
|
p53 |
< 0.02 |
Grignon et al. |
|||
|
Radiation dose |
< 0.001 |
Kupelian et al. |
|||
|
Prostate cancer with extension outside the prostate (advanced disease) |
|||||
|
|
|||||
|
Survival-associated prognosticators |
Progression-associated prognosticators |
||||
|
Prognosticator |
p value |
Reference |
Prognosticator |
p value |
Reference |
|
AR**** |
< 0.01 |
Segawa et al. |
Nuclear morphometry |
< 0.01 |
Partin et al. |
|
AR |
< 0.02 |
Miyoshi et al. |
Nuclear morphometry |
< 0.0003 |
Vesalainen et al. |
|
Total-PSA |
< 0.001 |
Bjork et al. |
Gleason score |
< 0.0001 |
Vesalainen et al. |
|
MVD |
< 0.0001 |
Borre et al. |
Gleason score |
< 0.007 |
Shurbaji et al. |
|
Ki-67 |
< 0.02 |
Aaltomaa et al. |
AR |
< 0.03 |
Sadi et al. |
|
p53 |
< 0.018 |
Bauer et al. |
|||
|
bcl-2 |
< 0.004 |
Bauer et al. |
|||
|
|
|||||
|
* Prostate Specific Antigen, ** Insulin-like Growth Factor, *** Microvessel density, **** Androgen Receptor |
|||||
|
Buhmeida et al. Diagnostic Pathology 2006 1:4 doi:10.1186/1746-1596-1-4 |
|||||